Latest news with #NeXTPersonal®
Business Wire
22-05-2025
- Health
- Business Wire
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal ® ultrasensitive ctDNA assay for residual and recurrent cancer detection. 'These studies continue to expand the clinical data for NeXT Personal into new areas, including neoadjuvant treatment in breast cancer and cervical cancer,' said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis. 'We continue to be driven by our mission to provide physicians and their patients better tools for guiding treatment through earlier, more sensitive, and more accurate detection of residual and recurrent cancer.' The presentations are as follows (all times CDT): Clinical Science Symposium: Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial) Session: Breast Cancer Time: Location: Arie Crown Theater/Live Stream Presenter: Natasha Hunter, MD, University of Washington Oral Presentation: Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses Session: Gynecologic Cancer Time: June 2, 2025, 8:48 AM - 9:00 AM Location: Room S100a (Grand Ballroom) - McCormick Place South (Level 1)/Live Stream Presenter: Jyoti Mayadev, MD, University of California San Diego Medical Center Poster Presentation: Ultrasensitive circulating tumor DNA (ctDNA) detection for prognostication in triple-negative breast cancer (TNBC) post-neoadjuvant chemotherapy (NAC) Session: Breast Cancer—Local/Regional/Adjuvant Time: June 2, 2025, 9:00 AM - 12:00 PM Location: Hall A, poster bd 145 - McCormick Place South (Level 1) Presenter: Luc Cabel, MD, PhD, Institut Curie, Paris, France Poster Presentation: Ultrasensitive ctDNA monitoring to reveal early predictors of immunotherapy success in advanced cancer Session: Developmental Therapeutics—Immunotherapy Time: June 2, 2025, 1:30 PM - 4:30 PM Location: Hall A, poster bd 208 - McCormick Place South (Level 1) Presenter: Charles Abbott, PhD, Personalis, Inc., Fremont, CA About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are 'forward-looking statements' within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect residual and recurrent cancer earlier, more sensitively, and more accurately, guide treatment, monitor a patient's response to therapy, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the presentations and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO.
Yahoo
22-04-2025
- Business
- Yahoo
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
FREMONT, Calif., April 22, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company's NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, Illinois. "Our collaborators are excited to present new data, including initial results from the VICTORI study where NeXT Personal is being used to identify residual and recurrent colorectal cancer in patients. With a more sensitive test, our goal is to improve patient outcomes by finding and treating colorectal cancer recurrence earlier. We are also thrilled that NeXT Personal results from the TRACERx collaboration, one of the largest ctDNA studies in early-stage lung cancer, will be presented at the meeting," said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis. The two oral presentations are: Oral Presentation: Detection of post-surgical minimal residual disease (MRD) in colorectal cancer; preliminary results from the VICTORI studyTime: April 28, 2025, 3:35 PM - 3:50 PMLocation: Room S105 - McCormick Place South (Level 1)Presenter: Emma Titmuss, BC Cancer, Vancouver, BC, Canada Oral Presentation: Ultrasensitive MRD detection: Results from TRACERxTime: April 28, 2025, 12:35 PM - 12:55 PMLocation: Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)Presenter: Charles Swanton, The Francis Crick Institute, London, United Kingdom Additionally, a poster presentation detailing results from clinical NeXT Personal testing across >15 different cancer types will be presented: Poster Presentation: Impact of an ultrasensitive ctDNA test on MRD detection in real world clinical patient testingTime: April 29, 2025, 9:00 AM - 12:00 PMLocation: Section 29, poster 4549Presenter: Rachel Marty Pyke, Personalis, Inc., Fremont, CA About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor a patient's response to therapy, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by AACR. View source version on Contacts Investors: Caroline Cornerinvestors@ 415-202-5678 Media Contact pr@ Sign in to access your portfolio
Business Wire
22-04-2025
- Business
- Business Wire
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company's NeXT Personal ® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, Illinois. 'Our collaborators are excited to present new data, including initial results from the VICTORI study where NeXT Personal is being used to identify residual and recurrent colorectal cancer in patients. With a more sensitive test, our goal is to improve patient outcomes by finding and treating colorectal cancer recurrence earlier. We are also thrilled that NeXT Personal results from the TRACERx collaboration, one of the largest ctDNA studies in early-stage lung cancer, will be presented at the meeting,' said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis. The two oral presentations are: Oral Presentation: Detection of post-surgical minimal residual disease (MRD) in colorectal cancer; preliminary results from the VICTORI study Time: April 28, 2025, 3:35 PM - 3:50 PM Location: Room S105 - McCormick Place South (Level 1) Presenter: Emma Titmuss, BC Cancer, Vancouver, BC, Canada Oral Presentation: Ultrasensitive MRD detection: Results from TRACERx Time: Location: Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1) Presenter: Charles Swanton, The Francis Crick Institute, London, United Kingdom Additionally, a poster presentation detailing results from clinical NeXT Personal testing across >15 different cancer types will be presented: Poster Presentation: Impact of an ultrasensitive ctDNA test on MRD detection in real world clinical patient testing Time: April 29, 2025, 9:00 AM - 12:00 PM Location: Section 29, poster 4549 Presenter: Rachel Marty Pyke, Personalis, Inc., Fremont, CA About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are 'forward-looking statements' within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor a patient's response to therapy, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by AACR.
Yahoo
27-02-2025
- Business
- Yahoo
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
Full year revenue of $84.6 million represents a 15% year-over-year increase Cash balance of $185 million expected to provide runway to cash flow break-even FREMONT, Calif., February 27, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights. Recent Business Highlights Delivered 1,441 total molecular tests in the fourth quarter of 2024, an increase of 52% compared with 945 tests delivered in the third quarter of 2024; delivered 3,285 total molecular tests for the full year of 2024 compared with 177 in 2023 Submitted for Medicare coverage in early-stage breast cancer Collaborators have submitted manuscripts for publication in peer-reviewed journals for all three Personalis focus indications in breast and lung cancer and IO monitoring, with breast cancer accepted for publication Expanded the number of clinical studies in progress to over 20 Raised $50 million with Merck Sharp & Dohme LLC ("Merck") in a direct investment transaction Signed a multi-year extension with ModernaTX, Inc. ("Moderna") to utilize ImmunoID NeXT for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna Expanded the commercial agreement with Tempus AI, Inc. ("Tempus") to authorize Tempus to sell NeXT Personal® to pharmaceutical and biotechnology companies "In 2024, we executed very well and are starting 2025 confident our strategy is working and we will 'Win in MRD,'" said Chris Hall, Chief Executive Officer and President. "We expanded our partnership with Tempus, presented compelling clinical data at Medical Conferences, and drove testing growth 52% quarter over quarter ending the year with 1,441 molecular tests in the fourth quarter. Also, we announced a long-term commercial collaboration with Moderna and a strategic investment of $50 million from Merck, endorsing our technology platform and capabilities to support our partners' initiatives, and providing a pathway to cashflow break-even." Full Year 2024 Financial Results Compared with 2023 Revenue of $84.6 million for the full year of 2024 compared with $73.5 million, an increase of 15% Revenue from pharma tests and services, enterprise sales, clinical diagnostics, and other customers of $77.2 million for the full year of 2024 compared with $64.1 million, an increase of 20%, despite the expected decrease in revenue from Natera of 20% to $25.4 million for the full year of 2024 Revenue from population sequencing for the VA MVP of $7.4 million for the full year of 2024, compared with $9.4 million, a decrease of 21% Net loss of $81.3 million, and net loss per share of $1.37 based on a weighted-average basic and diluted share count of 59.3 million for the full year of 2024 compared with a net loss of $108.3 million, and net loss per share of $2.25 based on a weighted-average basic and diluted share count of 48.2 million Cash, cash equivalents, and short-term investments of $185.0 million as of December 31, 2024; includes the $50.0 million strategic investment from Merck; reduced cash usage from operations and capital equipment additions in 2024 to $46.8 million, compared with $67.2 million Fourth Quarter 2024 Financial Results Compared with 2023 Revenue of $16.8 million for the fourth quarter of 2024 compared with $19.7 million for the fourth quarter of 2023, a decrease of 15%, primarily due to the expected decline in revenue from Natera and the VA MVP Pharma tests and services, enterprise sales, clinical diagnostics, and other customers of $16.6 million for the fourth quarter of 2024 compared with $18.7 million for the fourth quarter of 2023, a decrease of 11% Population sequencing for the VA MVP of $0.2 million for the fourth quarter of 2024 compared with $1.0 million for the fourth quarter of 2023, a decrease of 78% Net loss of $16.4 million, and net loss per share of $0.23 based on a weighted-average basic and diluted share count of 72.9 million in the fourth quarter 2024 compared with a net loss of $26.6 million, and net loss per share of $0.54 based on a weighted-average basic and diluted share count of 49.6 million in the fourth quarter of 2023 First Quarter and Full Year 2025 Outlook Personalis expects the following for the first quarter of 2025: Total company revenue to be in the range of $17 to $18 million Revenue from pharma tests and services, and all other customers to be in the range of $10 to $11 million Revenue from population sequencing and enterprise sales of approximately $7 million Personalis expects the following for the full year of 2025: Total company revenue in the range of $80 to $90 million Revenue from pharma tests and services, and all other customers in the range of $62 to $64 million Revenue from population sequencing and enterprise sales in the range of $15 to $16 million Revenue from clinical tests reimbursed in the range of $3 to $10 million Gross margin in the range of 21% to 23%, which is lower than the 32% gross margin for the full year of 2024 as we invest to drive clinical usage ahead of reimbursement. Net loss of approximately $85 million Cash usage in the range of $75 to $80 million, which is an increase from the $47 million used in 2024 primarily due to investments in the next phase of our "Win in MRD" strategy, inclusive of growing our test volume, expanding clinical studies, and investing in commercial capabilities to drive growth Webcast and Conference Call Information Personalis will host a conference call to discuss the fourth quarter and full year 2024 financial results, as well as plans for 2025, after market close on Thursday, February 27, 2025, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar can be accessed at A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as "anticipate," "estimate," "expect," "if," "may," "future," "will" or similar expressions. These statements include statements relating to: Personalis' first quarter and full year 2025 financial guidance, the benefits of the collaboration with Moderna and the strategic investment from Merck and the ability of Personalis to support their and other partners' initiatives, and the potential for Personalis to achieve cashflow break-even in the future. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the timing and pace of new orders from customers, including from Moderna, Merck, and VA MVP; the success of Personalis' clinical sales team's and Tempus's sales and marketing efforts; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; Personalis' ability to demonstrate attributes, advantages or clinical validity of the NeXT platform; the rate of adoption and use of the NeXT platform; the expected benefits of Personalis' extended collaboration with Moderna and the strategic investment from Merck; Personalis' ability to obtain Medicare coverage and reimbursement; the benefits of Personalis' investments in growing clinical test volume and its commercial capabilities; the expansion of clinical studies; and Personalis may opportunistically raise additional capital through equity offerings, debt financings, collaborations, or licensing arrangements. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission (SEC) on November 6, 2024 and in its Annual Report on Form 10-K for the year ended December 31, 2024, being filed with the SEC on February 27, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. PERSONALIS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 (unaudited) Revenue (1) $ 16,800 $ 19,675 $ 84,614 $ 73,481 Costs and expenses Cost of revenue 12,250 14,470 57,789 55,273 Research and development 11,494 13,613 48,905 64,776 Selling, general and administrative (2) 11,168 11,524 46,187 49,726 Lease impairment — — — 5,565 Restructuring and other charges — 4,040 — 8,077 Total costs and expenses 34,912 43,647 152,881 183,417 Loss from operations (18,112 ) (23,972 ) (68,267 ) (109,936 ) Interest income 1,631 1,477 5,510 5,901 Interest expense 1 (9 ) (24 ) (110 ) Other income (expense), net (3) 59 (4,075 ) (18,485 ) (4,068 ) Loss before income taxes (16,421 ) (26,579 ) (81,266 ) (108,213 ) Provision for income taxes 4 5 18 83 Net loss $ (16,425 ) $ (26,584 ) $ (81,284 ) $ (108,296 ) Net loss per share, basic and diluted $ (0.23 ) $ (0.54 ) $ (1.37 ) $ (2.25 ) Weighted-average shares outstanding, basic and diluted 72,879,436 49,596,698 59,251,013 48,175,201 (1) Includes related party revenue of $2.0 million for three and twelve months ended December 31, 2024. (2) Includes related party sales and marketing expenses of $0.2 million and $0.5 million for the three and twelve months ended December 31, 2024, respectively. (3) Includes related party other expense of $18.3 million in connection with the change in fair value of Tempus Warrants for the twelve months ended December 31, 2024. PERSONALIS, INC. SUPPLEMENTAL REVENUE INFORMATION (in thousands) Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 (unaudited) Pharma tests and services (1) $ 12,232 $ 11,491 $ 50,939 $ 31,904 Enterprise sales 4,170 7,073 25,364 31,729 Population sequencing 219 1,007 7,430 9,412 Clinical diagnostic 176 33 759 38 Other 3 71 122 398 Total revenue $ 16,800 $ 19,675 $ 84,614 $ 73,481 (1) Includes related party revenue of $2.0 million for the three and twelve months ended December 31, 2024. PERSONALIS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) December 31, 2024 2023 Assets Current assets Cash and cash equivalents $ 91,415 $ 56,984 Short-term investments 93,594 57,195 Accounts receivable, net (1) 8,140 17,730 Inventory and other deferred costs 5,939 10,474 Prepaid expenses and other current assets 3,927 4,361 Total current assets 203,015 146,744 Property and equipment, net 48,274 57,366 Operating lease right-of-use assets 16,453 17,852 Other long-term assets 2,526 3,137 Total assets $ 270,268 $ 225,099 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 6,397 $ 14,920 Accrued and other current liabilities (2) 21,629 23,941 Contract liabilities 3,100 3,288 Short-term warrant liability — 5,085 Total current liabilities 31,126 47,234 Long-term operating lease liabilities 34,882 38,321 Long-term warrant liability — 4,942 Other long-term liabilities (3) 1,303 5,161 Total liabilities 67,311 95,658 Commitments and contingencies Stockholders' equity Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued — — Common stock, $0.0001 par value — 200,000,000 shares authorized; 85,171,146 and 50,480,694 shares issued and outstanding, respectively 9 5 Additional paid-in capital 752,961 598,364 Accumulated other comprehensive loss (23 ) (222 ) Accumulated deficit (549,990 ) (468,706 ) Total stockholders' equity 202,957 129,441 Total liabilities and stockholders' equity $ 270,268 $ 225,099 (1) Includes related party accounts receivable of $2.5 million as of December 31, 2024. (2) Includes related party liabilities of $1.7 million as of December 31, 2024. (3) Includes related party liabilities of $1.2 million as of December 31, 2024. View source version on Contacts Investor Relations Contact:Caroline Cornerinvestors@ 415-202-5678 Media:pr@ Sign in to access your portfolio
